Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel
Authors:
Open Access
- 1 January 2023
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 9 (1) , e12375
Abstract
The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical Dementia Rating scale and Alzheimer's Disease Assessment Scale–Cognitive Subscale being among the most often used instruments in AD clinical trials. In contrast, there are no validated instruments for use in clinical trials of drugs for the treatment of dementia with Lewy bodies. This poses challenges for drug development because the regulatory pathway to drug approval requires demonstrable efficacy measures. In December 2021, the Lewy Body Dementia Association advisory group met with representatives from the US Food and Drug Administration to discuss the lack of approved drugs and treatments, discernment of efficacy measures, and identification of biomarkers. Highlights: The Lewy Body with Dementia Association convened a listening session with the US Food and Drug Administration on dementia with Lewy bodies (DLB) and clinical trial design. Gaps include DLB‐specific measures, alpha synuclein biomarkers, and coexisting pathologies. DLB clinical trial design should focus on clinical value and disease specificity.Keywords
Funding Information
- Lewy Body Dementia Association (P30 AG072959, P20 AG068053, R01AG022304, R01 AG057552, R01 AG070736, R56 AG074001, RF1 AG071566, U01 AG073323, U01 NS100610, R01 AG071514, R01 NS101483, R01 NS101483‐S1, P01 AG066584, R01 AG071643, R01 AG069765, R01 AG057681, P30 AG059295, U19‐AG062418)
- National Institutes of Health (NIH R01AG059008, NIH P30 AG072980, NIH R01AG073212)
This publication has 17 references indexed in Scilit:
- Advances in the pharmacotherapeutic management of dementia with Lewy bodiesExpert Opinion on Pharmacotherapy, 2018
- Diagnosis and management of dementia with Lewy bodiesNeurology, 2017
- The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic ReviewCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2016
- Lewy body dementiasThe Lancet, 2015
- The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosisAlzheimer's Research & Therapy, 2014
- α-Synucleinopathy phenotypesParkinsonism & Related Disorders, 2014
- Treatment of Dementia With Lewy BodiesCurrent Treatment Options in Neurology, 2013
- Incidence of Dementia With Lewy Bodies and Parkinson Disease DementiaJAMA Neurology, 2013
- Patients with Lewy body dementia use more resources than those with Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2006
- More Severe Functional Impairment in Dementia With Lewy Bodies Than Alzheimer Disease Is Related to Extrapyramidal Motor DysfunctionThe American Journal of Geriatric Psychiatry, 2006